IL240739A0 - Derivatives of betulinic acid that are modified by c-3 alkyl and alkenyl used to treat HIV - Google Patents

Derivatives of betulinic acid that are modified by c-3 alkyl and alkenyl used to treat HIV

Info

Publication number
IL240739A0
IL240739A0 IL240739A IL24073915A IL240739A0 IL 240739 A0 IL240739 A0 IL 240739A0 IL 240739 A IL240739 A IL 240739A IL 24073915 A IL24073915 A IL 24073915A IL 240739 A0 IL240739 A0 IL 240739A0
Authority
IL
Israel
Prior art keywords
hiv
alkyl
treatment
acid derivatives
betulinic acid
Prior art date
Application number
IL240739A
Other languages
English (en)
Hebrew (he)
Original Assignee
Viiv Healthcare Uk No 5 Ltd
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Uk No 5 Ltd, Bristol Myers Squibb Co filed Critical Viiv Healthcare Uk No 5 Ltd
Publication of IL240739A0 publication Critical patent/IL240739A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL240739A 2013-02-25 2015-08-20 Derivatives of betulinic acid that are modified by c-3 alkyl and alkenyl used to treat HIV IL240739A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361768630P 2013-02-25 2013-02-25
PCT/US2014/017688 WO2014130810A1 (en) 2013-02-25 2014-02-21 C-3 alkyl and alkenyl modified betulinic acid derivatives useful in the treatment of hiv

Publications (1)

Publication Number Publication Date
IL240739A0 true IL240739A0 (en) 2015-10-29

Family

ID=50288267

Family Applications (1)

Application Number Title Priority Date Filing Date
IL240739A IL240739A0 (en) 2013-02-25 2015-08-20 Derivatives of betulinic acid that are modified by c-3 alkyl and alkenyl used to treat HIV

Country Status (15)

Country Link
US (1) US9249180B2 (OSRAM)
EP (1) EP2958930A1 (OSRAM)
JP (1) JP6186012B2 (OSRAM)
KR (1) KR20150121712A (OSRAM)
CN (1) CN105102468A (OSRAM)
AR (1) AR094876A1 (OSRAM)
AU (1) AU2014218754B2 (OSRAM)
BR (1) BR112015019590A2 (OSRAM)
CA (1) CA2902513A1 (OSRAM)
EA (1) EA027861B1 (OSRAM)
IL (1) IL240739A0 (OSRAM)
MX (1) MX2015010354A (OSRAM)
SG (1) SG11201506445PA (OSRAM)
TW (1) TW201444862A (OSRAM)
WO (1) WO2014130810A1 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
US10221208B2 (en) * 2015-04-14 2019-03-05 ViiV Healthcare UK (No.4) Limited Methods of producing an HIV maturation inhibitor
EA038890B1 (ru) 2015-11-02 2021-11-03 Блюпринт Медсинс Корпорейшн Ингибиторы ret
AR107512A1 (es) 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
AR107912A1 (es) 2016-03-17 2018-06-28 Blueprint Medicines Corp Inhibidores de ret
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
WO2018022761A1 (en) 2016-07-27 2018-02-01 Blueprint Medicines Corporation Substituted cyclopentane-amides for treating disorders related to ret
WO2018044838A1 (en) * 2016-08-31 2018-03-08 Viiv Healthcare Company Combinations and uses and treatments thereof
CN106749486A (zh) * 2016-11-30 2017-05-31 沈阳化工大学 一种以乙二胺为连接臂的齐墩果酸衍生物及其应用
RU2020113341A (ru) 2017-09-14 2021-10-15 Феникс Байотекнолоджи, Инк. Способ и композиция для лечения вирусной инфекции
EP3681477A4 (en) 2017-09-14 2021-06-09 Phoenix Biotechnology, Inc. PROCEDURES AND IMPROVED COMPOSITION FOR TREATMENT OF TREITERPEN RESPONSIBLE CONDITIONS, DISEASES, OR DISORDERS
CA3096043A1 (en) 2018-04-03 2019-10-10 Blueprint Medicines Corporation Ret inhibitor for use in treating cancer having a ret alteration
HRP20231582T1 (hr) 2019-02-11 2024-03-15 Hetero Labs Limited Novi derivati triterpena kao inhibitori hiv-a
CN111440151A (zh) * 2020-03-25 2020-07-24 魏威 制备抗肿瘤药普拉赛替尼的方法
CN111362923A (zh) * 2020-03-25 2020-07-03 魏威 制备ret抑制剂普拉塞替尼的方法、以及普拉塞替尼的中间体及其制备方法
JP7153083B2 (ja) 2020-03-31 2022-10-13 フェニックス・バイオテクノロジー・インコーポレイテッド コロナウイルス感染を治療するための方法および組成物
EP4295854A3 (en) 2020-03-31 2024-04-03 Phoenix Biotechnology, Inc. Method and compositions for treating coronavirus infection
KR20230017234A (ko) 2020-05-29 2023-02-03 블루프린트 메디신즈 코포레이션 프랄세티닙의 고체 형태

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
US6369101B1 (en) * 1999-02-26 2002-04-09 Regents Of The University Of Minnesota Therapeutic method to treat herpes virus infection
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
MXPA06010592A (es) 2004-03-17 2007-06-12 Panacos Pharmaceuticals Inc Sales farmaceuticas de acido 3-o-(3',3'-dimetilsuccinil) betulinico.
TW200628161A (en) 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
US20110144069A1 (en) 2006-10-16 2011-06-16 Myriad Genetics, Incorporated Compounds for treating viral infections
EP2257567A1 (en) 2008-02-14 2010-12-08 Virochem Pharma Inc. Novel 17 beta lupane derivatives
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
CN103038245B (zh) * 2010-06-04 2015-03-25 百时美施贵宝公司 作为hiv成熟抑制剂的c-3经修饰的桦木酸衍生物
MX2012013628A (es) 2010-06-04 2012-12-17 Bristol Myers Squibb Co Amidas c-28 de derivados del acido betulinico c-3 modificados como inhibidores de la maduracion del virus de inmunodeficiencia humana (vih).
US8846647B2 (en) 2011-01-31 2014-09-30 Bristol-Myers Squibb Company C-17 and C-3 modified triterpenoids with HIV maturation inhibitory activity
RS54352B1 (sr) 2011-01-31 2016-02-29 Bristol-Myers Squibb Company C-28 amini c-3 modifikovanih derivata betulinske kiseline kao inhibitori sazrevanja hiv-a
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity

Also Published As

Publication number Publication date
CN105102468A (zh) 2015-11-25
EP2958930A1 (en) 2015-12-30
SG11201506445PA (en) 2015-09-29
KR20150121712A (ko) 2015-10-29
EA027861B1 (ru) 2017-09-29
CA2902513A1 (en) 2014-08-28
TW201444862A (zh) 2014-12-01
US20140243298A1 (en) 2014-08-28
AR094876A1 (es) 2015-09-02
BR112015019590A2 (pt) 2017-07-18
EA201591545A1 (ru) 2015-12-30
WO2014130810A1 (en) 2014-08-28
AU2014218754A1 (en) 2015-10-15
MX2015010354A (es) 2015-10-09
JP6186012B2 (ja) 2017-08-23
US9249180B2 (en) 2016-02-02
AU2014218754B2 (en) 2017-04-20
JP2016509062A (ja) 2016-03-24

Similar Documents

Publication Publication Date Title
IL240739A0 (en) Derivatives of betulinic acid that are modified by c-3 alkyl and alkenyl used to treat HIV
IL264541B (en) The history of sulfamoylpyrrolamide and their use as drugs to treat jaundice b
IL242141B (en) The history of sulfamoylthiophenamide and their use as drugs to treat jaundice b
IL243410B (en) The history of glyoxamide-converted pyrrolamide and their use as drugs for the treatment of hepatitis b
IL241110A0 (en) n-phenyl-carboxamide derivatives and their use as drugs for the treatment of type b jaundice
ZA201405819B (en) Lupane triterpenoid derivatives and pharmaceutical use thereof
ZA201508545B (en) Derivatives of dolastatin 10 and auristatins
IL260741B (en) C-3 and c-17 modified triterpenoids as hiv-1 inhibitors
AP2015008814A0 (en) Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b